Catalyst Crew Technologies Corp. (OTC: CCTC), an artificial intelligence-driven healthcare technology company focused on scalable digital health solutions for emerging markets, announced today that its Chief Executive Officer, Kevin Roldan Levy, has initiated a capital structure initiative. Under the plan, up to fifty percent of his restricted common stock holdings are expected to be canceled in exchange for a newly designated class of preferred equity.
This initiative is intended to support the Company’s broader capital structure objectives, including optimization of its common equity base, enhancement of long-term strategic flexibility, and alignment of executive equity participation with broader corporate development goals. Management believes that the transaction will contribute to a more disciplined equity framework and support the Company’s evolving long-term strategic initiatives, including future financing opportunities, strategic partnerships, and broader operational development.
The Company also stated that this capital structure initiative is expected to strengthen alignment between executive leadership and long-term corporate performance objectives while reinforcing management’s commitment to disciplined growth and shareholder-oriented development. “This initiative reflects my long-term commitment to the Company’s strategic development and disciplined capital structure management,” said Kevin Roldan Levy. “As we continue advancing our broader healthcare technology strategy, I believe proactive capital structure planning will support stronger long-term positioning while reinforcing our commitment to sustainable shareholder value creation.”
The Company is currently finalizing the structure and designation of the new preferred equity as part of the implementation process and expects to provide additional updates as final corporate actions are completed. Catalyst Crew continues to advance its transition into AI-enabled healthcare, with a focus on telehealth infrastructure, remote patient monitoring, and data-driven clinical insights across underserved markets.
This move comes as the Company, which has not yet generated revenues from its current business direction, positions itself for growth. The capital structure restructuring could signal to potential investors and partners a more disciplined approach to equity management. By reducing the common share overhang and aligning executive incentives, Catalyst Crew may enhance its attractiveness for future financing and strategic collaborations.
For more information, visit https://catalystcrewai.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov. The Company will continue to evaluate strategic initiatives designed to support its long-term development and will provide additional updates as appropriate.
